These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 34663943)

  • 1. The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs.
    Diepstraten ST; Anderson MA; Czabotar PE; Lessene G; Strasser A; Kelly GL
    Nat Rev Cancer; 2022 Jan; 22(1):45-64. PubMed ID: 34663943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymphoma cells lacking pro-apoptotic BAX are highly resistant to BH3-mimetics targeting pro-survival MCL-1 but retain sensitivity to conventional DNA-damaging drugs.
    Diepstraten ST; Young S; La Marca JE; Wang Z; Kluck RM; Strasser A; Kelly GL
    Cell Death Differ; 2023 Apr; 30(4):1005-1017. PubMed ID: 36755070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias.
    Thijssen R; Diepstraten ST; Moujalled D; Chew E; Flensburg C; Shi MX; Dengler MA; Litalien V; MacRaild S; Chen M; Anstee NS; Reljić B; Gabriel SS; Djajawi TM; Riffkin CD; Aubrey BJ; Chang C; Tai L; Xu Z; Morley T; Pomilio G; Bruedigam C; Kallies A; Stroud DA; Bajel A; Kluck RM; Lane SW; Schoumacher M; Banquet S; Majewski IJ; Strasser A; Roberts AW; Huang DCS; Brown FC; Kelly GL; Wei AH
    Blood; 2021 May; 137(20):2721-2735. PubMed ID: 33824975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines.
    Merino D; Kelly GL; Lessene G; Wei AH; Roberts AW; Strasser A
    Cancer Cell; 2018 Dec; 34(6):879-891. PubMed ID: 30537511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The first MCL-1-selective BH3 mimetics have therapeutic potential for chronic lymphocytic leukemia.
    Besbes S; Pocard M; Mirshahi M; Billard C
    Crit Rev Oncol Hematol; 2016 Apr; 100():32-6. PubMed ID: 26899021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New dimension in therapeutic targeting of BCL-2 family proteins.
    Besbes S; Mirshahi M; Pocard M; Billard C
    Oncotarget; 2015 May; 6(15):12862-71. PubMed ID: 25970783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What can we learn from mice lacking pro-survival BCL-2 proteins to advance BH3 mimetic drugs for cancer therapy?
    Brinkmann K; Ng AP; de Graaf CA; Strasser A
    Cell Death Differ; 2022 Jun; 29(6):1079-1093. PubMed ID: 35388168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BCL-W makes only minor contributions to MYC-driven lymphoma development.
    Diepstraten ST; La Marca JE; Chang C; Young S; Strasser A; Kelly GL
    Oncogene; 2023 Sep; 42(37):2776-2781. PubMed ID: 37567974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BH3 mimetic drugs cooperate with Temozolomide, JQ1 and inducers of ferroptosis in killing glioblastoma multiforme cells.
    Moujalled D; Southon AG; Saleh E; Brinkmann K; Ke F; Iliopoulos M; Cross RS; Jenkins MR; Nhu D; Wang Z; Shi MX; Kluck RM; Lessene G; Grabow S; Bush AI; Strasser A
    Cell Death Differ; 2022 Jul; 29(7):1335-1348. PubMed ID: 35332309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BH3 mimetics: status of the field and new developments.
    Billard C
    Mol Cancer Ther; 2013 Sep; 12(9):1691-700. PubMed ID: 23974697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitochondrial Profiling of Acute Myeloid Leukemia in the Assessment of Response to Apoptosis Modulating Drugs.
    Ishizawa J; Kojima K; McQueen T; Ruvolo V; Chachad D; Nogueras-Gonzalez GM; Huang X; Pierceall WE; Dettman EJ; Cardone MH; Shacham S; Konopleva M; Andreeff M
    PLoS One; 2015; 10(9):e0138377. PubMed ID: 26375587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The BCL-2 arbiters of apoptosis and their growing role as cancer targets.
    Adams JM; Cory S
    Cell Death Differ; 2018 Jan; 25(1):27-36. PubMed ID: 29099483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting BCL-2-like Proteins to Kill Cancer Cells.
    Cory S; Roberts AW; Colman PM; Adams JM
    Trends Cancer; 2016 Aug; 2(8):443-460. PubMed ID: 28741496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The rise of apoptosis: targeting apoptosis in hematologic malignancies.
    Valentin R; Grabow S; Davids MS
    Blood; 2018 Sep; 132(12):1248-1264. PubMed ID: 30012635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BH3 Mimetic Peptides: An Effective Strategy to Complement Anticancer Therapy.
    Saraswathy SD; Mirunalini A; Karthikeyan K; Premkumar K
    Curr Protein Pept Sci; 2023; 24(10):853-864. PubMed ID: 37608654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies.
    Chen S; Dai Y; Pei XY; Myers J; Wang L; Kramer LB; Garnett M; Schwartz DM; Su F; Simmons GL; Richey JD; Larsen DG; Dent P; Orlowski RZ; Grant S
    Cancer Res; 2012 Aug; 72(16):4225-37. PubMed ID: 22693249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BECN1 and BIM interactions with MCL-1 determine fludarabine resistance in leukemic B cells.
    Sharma A; Singh K; Mazumder S; Hill BT; Kalaycio M; Almasan A
    Cell Death Dis; 2013 May; 4(5):e628. PubMed ID: 23681223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BCL-2 inhibition in haematological malignancies: Clinical application and complications.
    Fowler-Shorten DJ; Hellmich C; Markham M; Bowles KM; Rushworth SA
    Blood Rev; 2024 May; 65():101195. PubMed ID: 38523032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitophagy Promotes Resistance to BH3 Mimetics in Acute Myeloid Leukemia.
    Glytsou C; Chen X; Zacharioudakis E; Al-Santli W; Zhou H; Nadorp B; Lee S; Lasry A; Sun Z; Papaioannou D; Cammer M; Wang K; Zal T; Zal MA; Carter BZ; Ishizawa J; Tibes R; Tsirigos A; Andreeff M; Gavathiotis E; Aifantis I
    Cancer Discov; 2023 Jul; 13(7):1656-1677. PubMed ID: 37088914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
    Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
    Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.